Myriad is pioneering a new era of malignancy treatment and avoidance. The myRisk Hereditary Tumor test has the potential to reduce the burden of hereditary malignancy in the lives of people for generations to arrive, said Richard Wenstrup, M.D., chief medical officer, Myriad. myRisk represents a substantial new possibility to help physicians tailor treatment to people predicated on their genetic results as well as their personal and family history of cancer. Below are the key myRisk Hereditary Malignancy presentations getting highlighted at #ASCO15. BREAST Malignancy Podium Presentation S100BC: Predisposing Germline Mutations in HIGH QUALITY ER+HER2 – Breast Malignancy Patients Diagnosed <50 Years.The results of the immune workup were normal. The clinical span of the colitis was somewhat milder in Individual II-4 than it had been in her affected brother. In Family B, the index patient , who was of Lebanese descent, presented in her first year of life with severe enterocolitis associated with enteric fistulas, perianal abscesses, and chronic folliculitis, consistent with a diagnosis of Crohn’s disease . She required multiple surgical interventions, including colectomy and ileostomy . The histopathological evaluation of the specimen from the colon obtained during resection revealed circumscribed ulcerations of the mucosa, that pear-shaped intramural abscesses prolonged into the submucosa and muscularis propria .